Avapritinib
Systemic Mastocytosis With An Associated Clonal Hematologic Non-Mast Cell Lineage Disease
Blueprint Medicines CorporationSmall moleculePhase 2Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Systemic Mastocytosis With An Associated Clonal Hematologic Non-Mast Cell Lineage Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Midostaurin Jason Robert Gotlib | Phase 2 | B |
Bezuclastinib Cogent Biosciences, Inc. | Phase 2 | CCC |
Same molecule, other indications
Avapritinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →